Hans-Joachim Anders, Gema M Fernandez-Juarez, Augusto Vaglio, Paola Romagnani, Jürgen Floege
The management of immunoglobulin A nephropathy, membranous nephropathy, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated vasculitis, C3 glomerulonephritis, autoimmune podocytopathies and other immune-mediated glomerular disorders is focused on two major treatment goals, preventing overall mortality and the loss of kidney function. Since minimizing irreversible kidney damage best serves both goals, the management of immune-mediated kidney disorders must focus on the two central pathomechanisms of kidney function decline, i...
November 8, 2023: Nephrology, Dialysis, Transplantation